分子内叠氮酰氯的Schmidt反应合成(R)-苯并吲哚里西定

5-溴戊酰氯与手性助剂(S)-4-苄基-2-噁唑烷酮经酰胺化反应制得手性酰胺(3);3与叠氮钠反应得烷基化前体(4);以苄溴为烷基化试剂,碱辅助在酰胺羰基邻位引入苄基高立体选择性地制得手性酰胺[(R)-5],dr>99/1。用H2O2脱除(R)-5中的助剂结构单元得多米诺反应的前体手性叠氮羧酸[(R)-6];用草酰氯预处理(R)-6,原位制得叠氮酰氯,随即以四氯化锡来实现分子内Schmidt反应,苯环原位捕获重排中间体合成内酰胺[(R)-7],92%ee;用红铝还原(R)-7合成了(R)-苯并吲哚里西啶,收率85%,总收率40.6%,其结构经1H NMR,13C NMR和IR确证。     

3,3-二取代3-吲哚-3'-基氧化吲哚的立体选择性合成

以10 mol%(R,R)-环己二胺衍生的手性双功能硫脲叔胺(4b)为催化剂,3'-吲哚-3-氧化吲哚与α-氨基砜为原料,经3'-吲哚-3-氧化吲哚与原位生成的N-Boc芳香醛亚胺的不对称Mannich反应,合成了20个3,3-二取代3-吲哚-3'-基氧化吲哚类化合物(3a~3t),分离收率54%~98%,dr值90∶10~99∶1,其结构经~1H NMR,~(13)C NMR和HR-MS(ESI-TOF)表征。     

5-取代吲哚-2-酮的合成

4-取代苯胺依次与水合氯醛及盐酸羟胺反应制得4-取代异亚硝基乙酰苯胺(2a～2e);2在浓硫酸作用下环合制得5-取代靛红(3a～3e);3通过改进的Wolff-Kishner-黄鸣龙反应合成了重要的药物中间体——5-取代吲哚-2-酮(5a～5e);5a通过硝化制得5-硝基吲哚-2-酮(5f);5f被还原制得5-氨基吲哚-2-酮(5g)。其结构经1H NMR和MS确证。     

6b,11b-二羟基-9,9-二甲基-7-对甲氧基苯基-8,9,10,11b-四氢化6bH-苊并[1,2-b]吲哚-11(7H)-酮的合成和晶体结构

利用L-脯氨酸催化的烯胺酮(1)与苊醌(2)的加成、环化串联反应,合成得到了6b,11b-二羟基-9,9-二甲基-7-对甲氧基苯基-8,9,10,11b-四氢化6bH-苊并[1,2-b]吲哚-11(7 H)-酮(3).标题化合物的结构通过单晶X射线衍射法确定,晶体属于单斜晶系,空间群C2/c,相对分子质量M_r=427.48,晶胞参数a=3.187 0(6)nm,b=0.974 22(19)nm,c=1.364 8(3)nm,V=4.234 4(15)nm3,Z=8,晶胞密度Dc=1.341g·cm~(-3),吸收系数μ=0.090mm~(-1),单胞中电子的数目F(000)=1 808.晶体结构用直接法解出,经全矩阵最小二乘法对原子参数进行修正,最终的偏离因子为R=0.095 7,wR=0.272 4.在晶体结构中2个羟基处于顺式,通过分子间氢键形成二聚体.     

1,2-双(4-溴苯基)-6,7-二氢-3-甲氧基-6,6-二甲基-1H-吲哚-4(5H)-酮的简便合成和结构表征

以1-(4-溴苯基)-2,2-二羟基-乙酮、3-((4-溴苯基)氨基)-5,5-二甲基环己-2-烯酮为原料,甲醇既为醚化试剂也是反应介质,采用对-甲基苯磺酸(p-TsOH)为催化剂,通过多组分的多米诺反应微波辐射下合成多取代的四氢吲哚类衍生物--1,2-双(4-溴苯基)-6,7-二氢-3-甲氧基-6,6-二甲基-1H-吲哚-4(5H)-酮.其结构通过单晶X射线衍射法确定,晶体属三斜晶系,空间群P-1,相对分子质量Mr=503.23,晶胞参数a=0.884 19(9)nm,b=0.969 36(11)nm,c=1.348 97(13)nm,V=1.070 96(19)nm3,Z=2,晶胞密度Dc=1.561g/cm3,吸收系数μ=3.803mm-1,单胞中电子的数目F(000)=504.晶体结构用直接法解出,经全矩阵最小二乘法对原子参数进行修正,最终的偏离因子为.R=0.058 4,wR=0.107 8.在晶体结构中新形成的吡咯杂环近似于平面结构.     

新型异噁唑山酮素骨架螺环氧化吲哚类化合物的合成

本文以色酮-氧化吲哚合成子(1)与硝基异噁唑苯乙烯(2),催化剂DBU作用下,经分子间Michael加成,分子内Michael加成环化反应,获得7个新型异噁唑山酮素骨架螺环氧化吲哚类化合物3a~3g,产率87%~93%,dr=8/1~15/1, 其结构经¹H NMR, ¹³C NMR和HR-MS（ESI-TOF）表征。      

吲哚并四氢呋喃-咪唑盐杂合物的合成及细胞毒活性研究

从色醇出发,通过Sharpless环氧化、酰胺化、偶联和成盐四步反应合成了一系列新型的吲哚并四氢呋喃-咪唑盐杂合物,其结构经~1H NMR,~(13)CNMR,HRMS以及X射线单晶衍射确定.对合成的新化合物进行了体外抗肿瘤细胞毒活性筛选,结果表明,1-((3aR,8aS)-3,3a-二氢-3a-羟基-2H-呋喃并[2,3-b]吲哚-8(8aH)-基)乙酮-3-(2-(萘-2-基)-2-氧乙基)-5,6-二甲基-1H-苯并[d]咪唑-3-溴盐(20)和1-((3aR,8aS)-3,3a-二氢-3a-羟基-2H-呋喃并[2,3-b]吲哚-8(8aH)-基)乙酮-3-(2-萘甲基))-5,6-二甲基-1H-苯并[d]咪唑-3-溴盐(22)具有较好的体外肿瘤生长抑制活性,对SMMC-7721、MCF-7和SW-480肿瘤细胞株的活性均优于顺铂(DDP),1-((3aR,8aS)-3,3a-二氢-3a-羟基-2H-呋喃并[2,3-b]吲哚-8(8a H)-基)乙酮-3-(2-溴苄基))-5,6-二甲基-1H-苯并[d]咪唑-3-溴盐(24)对SW-480肿瘤细胞株表现出较好的选择性细胞毒活性,其IC_(50)值约为顺铂的2.0倍.     

异噁唑色满酮拼接螺环氧化吲哚类化合物的合成及其抗白血病细胞增殖活性

以色酮-氧化吲哚C₃合成子1与硝基异噁唑苯乙烯2为原料,在相转移催化剂碱性作用下,依次发生γ-位区域选择性Michael加成,分子内Michael加成环化反应,合成了8个新颖的异噁唑色满酮拼接螺环氧化吲哚类化合物3a~3h,产率42%~58%,dr值>20/1, 其结构经¹H NMR, ¹³C NMR和HR-MS（ESI-TOF）表征。采用MTT法研究了3a~3h对人白血病细胞(K562)的体外抗增殖活性。结果表明：化合物3b, 3d, 3f和3g对K562增殖具有一定的抑制活性。      

1-(4-(1H-吲哚-3-基)-2-甲基-5-苯基-1-对甲苯基-1H-吡咯-3-基)乙酮的简便合成和结构表征

标题化合物(C28H24N2O)以N-对甲苯基烯胺酮,2,2-二羟基-1-苯基乙酮和吲哚为原料,在醋酸溶剂中,经微波辐射合成得到.其结构通过单晶X射线衍射法确定,晶体属单斜晶系,空间群P21/n,相对分子质量Mr=404.49,晶胞参数a=0.806 93(8)nm,b=1.473 70(13)nm,c=1.865 12(18)nm,V=2.213 5(4)nm3,Z=4,晶胞密度Dc=1.214g/cm3,吸收系数μ=0.074mm-1,单胞中电子的数目F(000)=856.晶体结构用直接法解出,经全矩阵最小二乘法对原子参数进行修正,最终的偏离因子为R=0.0491,ωR=0.115 4.在晶体结构中新形成的吡咯杂环近似于平面结构.     

3-氨基-2-吲哚酮合成方法的改进

以苯胺为原料,通过传统方法合成靛红,靛红与盐酸羟胺反应生成3-羟基亚氨基-2-吲哚酮,再通过钯碳加氢还原生成3-氨基-2-吲哚酮。合成中,采用钯碳加氢的还原方式,产物收率提高(收率82.76%,较文献提高了11.8%),后处理更简单。该方法可操作性高、成本低、产生三废少,是一条适合大规模生产3-氨基-2-吲哚酮的新合成工艺路线。     

Asymmetric syntheses of (8R,8aS)- and (8R,8aR)-8-hydroxy-5-indolizidinones:Two promising oxygenated indolizidine building blocks

Starting from the oxygenated piperidine building block 20,two synthetic approaches to new building blocks (8R,8aS)-and (8R,8aR)-8-hydroxy-5-indolizidinones 19a/19b and 15a/15b have been developed,respectively. The first one is based on the trans-diastereoselective reductive alkylation (dr = 93:7),followed by a four-step procedure; and the second one called for the RCM reaction on the N,O-acetal derived from a vinylation,which was followed by a pyrrole formation,and a stereocontrolled cis-selective (dr = 91:...     

Enantio- and diastereoselective synthesis of (R,R)-beta-methoxytyrosine

The nonproteinogenic amino acid (2R,3R)-beta-methoxytyrosine, a constituent of several cyclic depsipeptide natural products, was synthesized in protected form (8) from a readily available cinnamate ester in four steps and 62% overall yield with a greater than 28:1 er and 19:1 dr. This method provides a highly efficient, enantio- and diastereoselective synthesis of an important amino acid.     

(1R,2S,5R,8S,9R,10S)-8-甲基-4-氮杂-5-苯基-7-氧杂四环[8.2.1.0~(2,9).0(~4,8)]十三-11-烯-3-酮的合成和晶体结构

为确定内型降冰片烯酰亚胺与甲基格氏试剂反应所得加成产物的结构,合成了标题化合物(C18H19NO2)。其结构通过单晶X-射线衍射分析确定,该晶体属正交晶系,空间群为P212121,a = 6.293(1),b = 14.342(3),c = 16.357(3) 牛琕 = 1476.2(5) ?,Z = 4,Dc = 1.266 g/cm3, (MoKa) = 0.082mm-1,F(000) = 600。晶体结构用直接法解出,最终的偏离因子为R = 0.0535,wR = 0.988。由此晶体结构可确定加成产物为标题化合物,并由1H-NMR数据推测另一加成产物的结构。     

光学纯的(4S, 8R)-和(4S, 8S)-1- 烯-8, 9-二醇的改进合成法

本文提出了一个改进的合成两个光学异构纯的94S)-1- 烯-8, 9-二醇的方法,其优点是简便、有效, 适于克量级制备。     

Synthesis and Crystal Structure of 5（R）-（1R,2S,5R）-Menthoxy-4（R）- N-cyclohexylaminobutyrolactone

1INTRODUCTION Substitutedγ-butyrolactones are a group of impor-tant compounds containing unique carbon skeleton of butyrolactone which is widely present in many natural products and have received considerable interest because of their biological and medicinal properties[1～4].Therefore,much attention has been paid to the new asymmetric methods for synthesi-zing these interesting compounds[5～11].The prece-ding results led us to explore the possibility of using cyclohexylamine to convert5(…     

New halide-centered discrete Ag(I)(8) cubic clusters containing diselenophosphate ligands, [Ag(8)(X)[Se(2)P(OR)(2)](6)](PF(6)) (X = Cl, Br; R = Et, Pr, (i)Pr): syntheses, structures, and DFT calculations

Six clusters Ag(8)(micro(8)-X)[Se(2)P(OR)(2)](6)(PF(6)) (R = Et, X = Cl, 1a, X = Br, 1b; R = Pr, X = Cl, 2a, X = Br, 2b; R = (i)Pr, X = Cl, 3a, X = Br, 3b) were isolated from the reaction of [Ag(CH(3)CN)(4)](PF(6)), NH(4)[Se(2)P(OR)(2)], and Bu(4)NX in a molar ratio of 4:3:1 in CH(2)X(2). Positive FAB mass spectra show m/z peaks at 2573.2 for 1a, 2617.3 for 1b, 2740.9 for 2a, 2786.9 for 2b, 2742.3 for 3a, and 2787.0 for 3b due to respective molecular cation, (M - PF(6))(+). (31)P NMR spectra of 1a-3b display a singlet at delta 82.3, 81.5, 82.9, 81.7, 76.3, and 75.8 ppm with a set of satellites (J(PSe) = 661, 664, 652, 652, 656, and 656 Hz, respectively). The X-ray structure (1a-2b) consists of a discrete cationic cluster in which eight silver ions are linked by six diselenophosphate ligands and a central micro(8)-Cl or micro(8)-Br ion with a noncoordinating PF(6)(-) anion. The shape of the molecule is a halide-centered distorted Ag(8) cubic cluster. The dsep ligand exhibits a tetrametallic tetraconnective (micro(2), micro(2)) coordination pattern, and each caps on a square face of the cube. Each silver atom of the cube is coordinated by three selenium atoms and the central chloride or bromide ion. Additionally, molecular orbital calculations at the B3LYP level of the density functional theory have been carried out to study the Ag-micro(8)-X (X = Cl, Br) interactions for cluster cations [Ag(8)(micro(8)-X)[Se(2)P(OR)(2)](6)](+). Calculations show very weak bonding interactions exist between micro(8)-X and Ag atoms of the cube.     

Chiroptische effekte von lanthanoidorganylen mit optisch aktiven liganden III. Erschließung wohldefinierter chiraler organosamarium(III)-verbindungen durch umsetzung von tris(cyclopentadienyl)samarium mit (1S,2R,5R)-Isomenthol, (R)-(+)-Isobutyllactat und (R)-(+)-Methyl-p-tolylsulfoxid

While each of the three organosamarium(III) title complexes: [Cp₂Sm{μ-OC₁₀H₁₉}]₂ (5; Cp = C₅H₅, OC₁₀H₁₉ = isomenthoxide), [Cp₂Sm{μ-OCH(Me)COOⁱBU}]₂ (6) and [Cp₃SmOS(Me)-p-C₆H₄Me] (7) contains a chiral ligand atom (i.e. C or S) next to the metal-bonded oxygen atoms, only the dinuclear compounds 5 and, even better, 6 display (below ca. 600 nm) significant circular dichroism of discrete f---f-crystal field transitions. According to a successful single-crystal X-ray study of 5, the cyclohexyl ring of its (1S,2R,5R)-isomenthoxide ligand adopts a conformation with axial OSm- and ⁱPr-substituents, which is energetically less favourable at least for neat (1S,2R,5R)-isomenthol.

Zusammenfassung

Obwohl jeder der drei neuen Organosamarium(III)-Komplexe: [Cp₂Sm{μ-OC₁₀OH₁₉}]₂ (5; Cp = C₅H₅, OC₁₀H₁₉ = Isomentholat), [Cp₂Sm{μ-OCH(Me)COOⁱBU}]₂ (6) und [Cp₃SmOS(Me)-p-C₆H₄Me] mindestens ein chirales Ligandenatom (C oder S) unmittelbar am metallkoordinierten O-Atom enthält, zeigen nur die dimeren Systeme 5 und noch ausgeprägter 6 (unterhalb von ca. 600 nm) signifikanten Circulardichroismus von f---f-Kristallfeldübergängen des Sm³⁺-Ions. Auf Grund einer erfolgreichen Kristallstrukturanalyse von 5 liegt der Cyclohexylring des (1S,2R,5R)-Isomentholatliganden ausschließlich in der Konformation mit axialen OSm- und ⁱPr-Substituenten vor, die für freies (1S,2R,5R)-Isomenthol energetisch deutlich unvorteilhafter ist.     

Synthesis and reactivity of Ir(I) and Ir(III) complexes with MeNH2, Me2C=NR (R = H, Me), C,N-C6H4{C(Me)=N(Me)}-2, and N,N'-RN=C(Me)CH2C(Me2)NHR (R = H, Me) ligands

Complexes [Ir(Cp*)Cl(n)(NH2Me)(3-n)]X(m) (n = 2, m = 0 (1), n = 1, m = 1, X = Cl (2a), n = 0, m = 2, X = OTf (3)) are obtained by reacting [Ir(Cp*)Cl(mu-Cl)]2 with MeNH2 (1:2 or 1:8) or with [Ag(NH2Me)2]OTf (1:4), respectively. Complex 2b (n = 1, m = 1, X = ClO 4) is obtained from 2a and NaClO4 x H2O. The reaction of 3 with MeC(O)Ph at 80 degrees C gives [Ir(Cp*){C,N-C6H4{C(Me)=N(Me)}-2}(NH2Me)]OTf (4), which in turn reacts with RNC to give [Ir(Cp*){C,N-C6H4{C(Me)=N(Me)}-2}(CNR)]OTf (R = (t)Bu (5), Xy (6)). [Ir(mu-Cl)(COD)]2 reacts with [Ag{N(R)=CMe2}2]X (1:2) to give [Ir{N(R)=CMe2}2(COD)]X (R = H, X = ClO4 (7); R = Me, X = OTf (8)). Complexes [Ir(CO)2(NH=CMe2)2]ClO4 (9) and [IrCl{N(R)=CMe2}(COD)] (R = H (10), Me (11)) are obtained from the appropriate [Ir{N(R)=CMe2}2(COD)]X and CO or Me4NCl, respectively. [Ir(Cp*)Cl(mu-Cl)]2 reacts with [Au(NH=CMe2)(PPh3)]ClO4 (1:2) to give [Ir(Cp*)(mu-Cl)(NH=CMe2)]2(ClO4)2 (12) which in turn reacts with PPh 3 or Me4NCl (1:2) to give [Ir(Cp*)Cl(NH=CMe2)(PPh3)]ClO4 (13) or [Ir(Cp*)Cl2(NH=CMe2)] (14), respectively. Complex 14 hydrolyzes in a CH2Cl2/Et2O solution to give [Ir(Cp*)Cl2(NH3)] (15). The reaction of [Ir(Cp*)Cl(mu-Cl)]2 with [Ag(NH=CMe2)2]ClO4 (1:4) gives [Ir(Cp*)(NH=CMe2)3](ClO4)2 (16a), which reacts with PPNCl (PPN = Ph3=P=N=PPh3) under different reaction conditions to give [Ir(Cp*)(NH=CMe2)3]XY (X = Cl, Y = ClO4 (16b); X = Y = Cl (16c)). Equimolar amounts of 14 and 16a react to give [Ir(Cp*)Cl(NH=CMe2)2]ClO4 (17), which in turn reacts with PPNCl to give [Ir(Cp*)Cl(H-imam)]Cl (R-imam = N,N'-N(R)=C(Me)CH2C(Me)2NHR (18a)]. Complexes [Ir(Cp*)Cl(R-imam)]ClO4 (R = H (18b), Me (19)) are obtained from 18a and AgClO4 or by refluxing 2b in acetone for 7 h, respectively. They react with AgClO4 and the appropriate neutral ligand or with [Ag(NH=CMe2)2]ClO4 to give [Ir(Cp*)(R-imam)L](ClO4)2 (R = H, L = (t)BuNC (20), XyNC (21); R = Me, L = MeCN (22)) or [Ir(Cp*)(H-imam)(NH=CMe2)](ClO4)2 (23a), respectively. The later reacts with PPNCl to give [Ir(Cp*)(H-imam)(NH=CMe2)]Cl(ClO4) (23b). The reaction of 22 with XyNC gives [Ir(Cp*)(Me-imam)(CNXy)](ClO4)2 (24). The structures of complexes 15, 16c and 18b have been solved by X-ray diffraction methods.     

Cluster-type basic lanthanide iodides [M6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)8 (M = Nd, Eu, Tb, Dy)

Ln6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)(8) (Ln = Nd, Eu, Tb, Dy) compounds are obtained as the final hydrolysis products of lanthanide triiodides in an aqueous solution. Their X-ray crystal structure features a body-centered arrangement of oxygen-centered {Ln6X8}8+ cluster cores: [Nd6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)8 [Pearson code oP156, orthorhombic, Pnnm (No. 58), Z = 2, a = 1310.4(3) pm, b = 1502.1(3) pm, c = 1514.9(3) pm, 3384 reflections with I0 > 2sigma(I0), R1 = 0.0340, wR2 = 0.0764, GOF = 1.022, T = 298(2) K], [Eu6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)8 [Pearson code oP156, orthorhombic, Pnnm (No. 58), Z = 2, a = 1306.6(2) pm, b = 1498.15(19) pm, c = 1499.41(18) pm, 4262 reflections with I0 > 2sigma(I0), R1 = 0.0540, wR2 = 0.0860, GOF = 0.910, T = 298(2) K], [Tb6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)8 [Pearson code oP156, orthorhombic, Pnnm (No. 58), Z = 2, a = 1296.34(5) pm, b = 1486.13(7) pm, c = 1491.88(6) pm, 4182 reflections with I0 > 2sigma(I0), R1 = 0.0395, wR2 = 0.0924, GOF = 1.000, T = 298(2) K], and [Dy6(mu6-O)(mu3-OH)8(H2O)24]I8(H2O)8 [Pearson code oP156, orthorhombic, Pnnm (No. 58), Z = 2, a = 1296.34(5) pm, b = 1486.13(7) pm, c = 1491.88(6) pm, 3329 reflections with I0 > 2sigma(I0), R1 = 0.0389, wR2 = 0.0801, GOF = 0.992, T = 298(2) K.     

Asymmetric strecker synthesis of alpha-amino acids via a crystallization-induced asymmetric transformation using (R)-phenylglycine amide as chiral auxiliary

[reaction: see text]. Diastereoselective Strecker reactions based on (R)-phenylglycine amide as chiral auxiliary are reported. The Strecker reaction is accompanied by an in situ crystallization-induced asymmetric transformation, whereby one diastereomer selectively precipitates and can be isolated in 76-93% yield and dr > 99/1. The diastereomerically pure alpha-amino nitrile obtained from pivaldehyde (R1 = t-Bu, R2 = H) was converted in three steps to (S)-tert-leucine in 73% yield and >98% ee.